Biohaven Ltd. Payments to Acquire Debt Securities, Available-for-sale
Biohaven Ltd. (BHVN) reported Payments to Acquire Debt Securities, Available-for-sale of $49.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-10
- Biohaven Ltd. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $29.72M, a 77.73% decline year-over-year.
- Biohaven Ltd. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $19.79M, a 55.69% decline year-over-year.
- Biohaven Ltd. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $88.73M, a 68.27% decline year-over-year.
- Biohaven Ltd. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Biohaven Ltd. payments to acquire debt securities, available-for-sale for fiscal 2025 was $266.88M, a 64.21% decline from fiscal 2024.
- Biohaven Ltd. payments to acquire debt securities, available-for-sale for fiscal 2024 was $745.68M, a 284.13% increase from fiscal 2023.
- Biohaven Ltd. payments to acquire debt securities, available-for-sale for fiscal 2023 was $194.12M, a 25.26% decline from fiscal 2022.
- Biohaven Ltd. payments to acquire debt securities, available-for-sale for fiscal 2022 was $259.72M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $49.51M 10-Q · filed 2026-08-10 | $138.24M derived: sum of 3 quarters · filed 2026-08-10 | $138.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $19.79M 10-Q · filed 2026-05-04 | $108.52M derived: sum of 2 quarters · filed 2026-05-04 | $108.52M derived: sum of 3 quarters · filed 2026-05-04 | $242.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $88.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $88.73M derived: sum of 2 quarters · filed 2026-03-02 | $222.22M derived: sum of 3 quarters · filed 2026-08-10 | $266.88M 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $133.48M derived: sum of 2 quarters · filed 2026-08-10 | $178.14M 10-Q · filed 2025-11-10 | $457.77M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $133.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $178.14M 10-Q · filed 2026-08-10 | $457.77M derived: sum of 3 quarters · filed 2026-08-10 | $680.56M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $44.66M 10-Q · filed 2026-05-04 | $324.29M derived: sum of 2 quarters · filed 2026-05-04 | $547.07M derived: sum of 3 quarters · filed 2026-05-04 | $743.26M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $279.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $502.41M derived: sum of 2 quarters · filed 2026-03-02 | $698.60M derived: sum of 3 quarters · filed 2026-03-02 | $745.68M 10-K · filed 2026-03-02 |
| 2024-09-30 | $222.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $418.97M derived: sum of 2 quarters · filed 2025-11-10 | $466.05M 10-Q · filed 2025-11-10 | $577.35M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $196.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $243.27M 10-Q · filed 2025-08-11 | $354.56M derived: sum of 3 quarters · filed 2026-03-02 | $384.01M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $47.08M 10-Q · filed 2025-05-12 | $158.38M derived: sum of 2 quarters · filed 2026-03-02 | $187.83M derived: sum of 3 quarters · filed 2026-03-02 | $211.38M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $111.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $140.75M derived: sum of 2 quarters · filed 2026-03-02 | $164.30M derived: sum of 3 quarters · filed 2026-03-02 | $194.12M 10-K · filed 2026-03-02 |
| 2023-09-30 | $29.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $53.00M derived: sum of 2 quarters · filed 2024-11-12 | $82.82M 10-Q · filed 2024-11-12 | $342.54M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $23.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $53.37M 10-Q · filed 2024-08-09 | $313.09M derived: sum of 3 quarters · filed 2025-03-03 | $313.09M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $29.82M 10-Q · filed 2024-05-09 | $289.54M derived: sum of 2 quarters · filed 2025-03-03 | $289.54M derived: sum of 3 quarters · filed 2025-03-03 | $289.54M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $259.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $259.72M derived: sum of 2 quarters · filed 2025-03-03 | $259.72M derived: sum of 3 quarters · filed 2025-03-03 | $259.72M 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $0.00 10-Q · filed 2023-07-31 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |